Pfizer Inc. (NYSE:PFE) ranks among the top picks for a retirement portfolio. BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on September 23 in response to the company’s announcement of a new agreement in the obesity treatment market. Pixabay/Public Domain Following disappointments with its lotiglipron and danuglipron programs, the pharmaceutical giant has now made what BMO Capital refers to as a “thoughtful re-entry into the obesity metabolic space” with its ...